RDHL - Healthcare Stock Briefly Climbs 100 Percent Wednesday

%Healthcare stocks have absolutely been dominating the headlines space. Earlier today we wrote about a biotech stock, and now we’re switching to a drug manufacturing company.

%RedhillBiopharma () turned heads during Wednesday’s session after the company announced the granting by the United States Patent and Trademark Office ( %USPTO ) of a further method of use patent that protects the administration of %Opaganib for the inhibition of a disease caused by a coronavirus, according to the release. Shares quickly climbed up to $0.96/share (+106.90%) at the session high.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.